Drug delivery methods for posterior segment disease

Current Opinion in Ophthalmology

Volumn 18, Issue 3, 2007, Pages 235-239

  Hsu, Jason ^a,b  

^a Wills Eye Institute   (United States)

^b WILLS EYE HOSPITAL   (United States)

Author keywords

Dexamethasone; Drug delivery; Fluocinolone acetonide; Uveitis

Indexed keywords

BEVACIZUMAB; CIDOFOVIR; CORTICOSTEROID; DEXAMETHASONE; DOXORUBICIN; FLUOCINOLONE ACETONIDE; FOSCARNET; GANCICLOVIR; LIPOSOME; MICROSPHERE; NANOPARTICLE; PEGAPTANIB; RANIBIZUMAB; TAMOXIFEN;

APPLICATION SITE BURNING; BIODEGRADABLE IMPLANT; BONE MARROW SUPPRESSION; CATARACT; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG TOLERABILITY; ELECTRIC CURRENT; ENDOPHTHALMITIS; EYE INFLAMMATION; GENERAL CONDITION IMPROVEMENT; HERPES SIMPLEX; HUMAN; INFECTION PREVENTION; IONTOPHORESIS; KIDNEY DYSFUNCTION; LIPID BILAYER; NONHUMAN; ORBIT DISEASE; PRIORITY JOURNAL; PTOSIS; RABBIT; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; RETINA TEAR; RETINITIS; REVIEW; SUBRETINAL NEOVASCULARIZATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS; VISUAL ACUITY; VITREORETINOPATHY; VITREOUS HEMORRHAGE;

ANIMALS; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEMS; HUMANS; MACULAR DEGENERATION; MACULAR EDEMA, CYSTOID; PHARMACEUTICAL PREPARATIONS; RETINAL VEIN OCCLUSION; UVEITIS, POSTERIOR;

EID: 34247215173     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3281108000     Document Type: Review

References (48)

1. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113:363-372. This was the first short-term retrospective case series demonstrating the efficacy of off-label intravitreal injections of bevacizumab for age-related macular degeneration.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. New Engl J Med 2006; 355:1419-1431. Two-year results of a multicenter randomized clinical trial of ranibizumab demonstrate its superior efficacy when given as monthly intravitreal injections in the treatment of age-related macular degeneration.
3. Ip MS, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 2004; 122:1131-1136.
4. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006; 26:279-284.
5. Kurz D, Ciulla TA. Novel approaches for retinal drug delivery. Ophthalmol Clin N Am 2002; 15:405-410.
6. Jabs DA, Enger C, Bartlett FG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989; 107:75-80.
7. Holland GN, Pepose JS, Pettit TH, et al. Acquired immune deficiency syndrome: ocular manifestations. Ophthalmology 1983; 90:859-873.
8. Jabs DA, Newman C, de Bustros S, et al. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 1987; 94:824-830.
9. Cantrill WH, Henry K, Melroe NH, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results. Ophthalmology 1989; 96:367-374.
10. Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med 1997; 335:83-90.
11. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol 1994; 112:1531-1539.
12. Shane TS, Martin DF. Endophthalmitis after ganciclovir implant in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 2003; 136:649-654.
13. Dunn JP, Van Natta M, Foster G, et al. Complications of ganciclovir implant surgery in patients with cytomegalovirus retinitis: the Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. Retina 2004; 24:41-50.
14. Martin DF, Dunn JP, Davis JL, et al. Use of ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panel. Am J Ophthalmol 1999; 127:329-339.
15. Gritz DC, Wong IG. Incidence and prevalence of uveitis in northern California. The Northern California Epidemiology of Uveitis Study. Ophthalmology 2004; 111:491-500.
16. Weiner A, BenEzra D. Clinical patterns and associated conditions in chronic uveitis. Am J Ophthalmol 1991; 112:151-158.
17. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996; 80:332-336.
18. Anglade E, Whitcup SM. The diagnosis and management of uveitis. Drugs 1995; 49:213-223.
19. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000; 130:492-513.
20. Haupert CL, Jaffe GL. New and emerging treatments for patients with uveitis. Int Ophthalmol Clin 2000; 40:205-220.
21. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitis cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001; 108:765-772.
22. Jaffe GJ, Yang CH, Guo H, et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000; 41:3569-3575.
23. Jaffe GJ, Ben-nun J, Guo J, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000; 107:2024-2033.
24. Jaffe GJ, McCallum RM, Branchaud B, et al. Long-term follow-up results of a pilot trial of fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 2005; 112:1192-1198.
25. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: 34-week results of a multicenter randomized clinical study. Ophthalmology 2006; 113:1020-1027. This is the most recent update of a 3-year multicenter study demonstrating the efficacy of the fluocinolone acetonide implant.
26. Pearson P, Levy B, Comstock T. Fluocinolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multicenter clinical trial [abstract]. Invest Ophthalmol Vis Sci 2006; 47:E-Abstract 5442.
27. Ramchandran RS, Stinett SS, Jaffe GJ. Fluocinolone acetonide sustained drug delivery device for chronic retinal venous occlusive disease [abstract]. Invest Ophthalmol Vis Sci 2006; 47:E-Abstract 5907.
28. Driot JY, Novack GD, Rittenhouse KD, et al. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocular Pharmacol Ther 2004; 20:269-275.
29. Lim JI, Wolitz RA, Dowling AH, et al. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1999; 127:288-293.
30. Bourges JL, Bloquel C, Thomas A, et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev 2006; 58:1182-1202. This is an excellent technical review of the current status of nonbiodegradable and biodegradable implant research.
31. Kuppermann BD, Williams GA, Blumenkranz MS, et al. Efficacy and safety of a novel intravitreous dexamethasone drug-delivery system after applicator or incisional placement in patients with macular edema [abstract]. Invest Ophthalmol Vis Sci 2006; 47:E-Abstract 5913.
32. Moshfeghi AA, Peyman GA. Micro- and nanoparticulates. Adv Drug Deliv Rev 2005; 57:2047-2052.
33. Moritera T, Ogura Y, Yoshmura N, et al. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1992; 33:3125-3130.
34. Bourges JL, Gautier SE, Delie F, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci 2003; 44:3562-3569.
35. Yasukara T, Ogura Y, Tabata Y, et al. Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res 2004; 23:253-281.
36. Ebrahim S, Peyman GA, Lee PJ. Applications of liposomes in ophthalmology. Surv Ophthalmol 2005; 50:167-182.
37. Kuppermann BD, Assil KK, Vuong C, et al. Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine for long-acting therapy of viral retinitis. J Infect Dis 1996; 173:18-23.
38. Bochot A, Couvreur P, Fattal E. Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog Retin Eye Res 2000; 19:131-147.
39. Peyman GA, Khoobehi B, Tawakol M, et al. Intravitreal injection of liposome-encapsulated ganciclovir in a rabbit model. Retina 1987; 7:227-229.
40. Myles ME, Neumann DM, Hill JM. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev 2005; 57:2063-2079.
41. Behar-Cohen FF, Parel JM, Pouliquen Y, et al. Iontophoresis of dexamethasone in the treatment of endotoxin-induced-uveitis in rats. Exp Eye Res 1997; 65:533-545.
42. Yoshizumi MO, Dessouki A, Lee DA, Lee G. Determination of ocular toxicity in multiple applications of foscarnet iontophoresis. J Ocular Pharmacol Ther 1997; 13:529-536.
43. Parkinson TM, Ferguson E, Febraro S, et al. Tolerance of ocular iontophoresis in healthy volunteers. J Ocular Pharmacol Ther 2003; 19:145-151.
44. Ambati J, Gragoudas ES, Miller JW, et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci 2000; 41:1186-1191.
45. Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci 2000; 41:1181-1185.
46. Moritera T, Ogura Y, Yoshimura N, et al. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1992; 33:3125-3130.
47. Carrasquillo KG, Ricker JA, Rigas IK, et al. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic) acid microspheres. Invest Ophthalmol Vis Sci 2003; 44:290-299.
48. de Kozak Y, Andrieux K, Villarroya H, et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol 2004; 34:3702-3712.